Nasdaq to delist BioXcel Therapeutics after Chapter 11 filing
Nasdaq notified BioXcel Therapeutics that its common stock will be delisted due to its Chapter 11 filing on Aug. 27, 2026. Trading will be suspended at the open on Sept. 8, 2026, with a Form 25-NSE to follow.
On August 31, 2026, Nasdaq notified the company that its common stock will be delisted due to the company's Chapter 11 filing on August 27, 2026.
Trading will be suspended at the open on September 8, 2026, and Nasdaq will file a Form 25-NSE to remove the stock from listing and registration.
The com…